NRx Pharmaceuticals, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024. For Q4 2024, the company reduced its loss from operations by approximately $2.0 million to $2.4 million, a 45% improvement compared to $4.4 million in Q4 2023.
For the full year 2024, loss from operations decreased by approximately $9.3 million, or 33.5%, to $18.5 million from $27.8 million in 2023. Research and development expenses for the year decreased by $7.2 million (53.6%) to $6.2 million, primarily due to the conclusion of the Phase 2b/3 study for NRX-101.
As of December 31, 2024, the company had approximately $1.4 million in cash and cash equivalents. In January 2025, NRx completed financings with aggregate gross proceeds of $8.5 million, which management believes will support operations through at least the end of 2025. The company also filed Module 3 of its NDA for NRX-100 in Q4 2024 and plans to file an ANDA for preservative-free ketamine in Q2 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.